AstraZeneca PLC (LON:AZN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is £153.57.
A number of research firms have weighed in on AZN. Citigroup lifted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Berenberg Bank restated a “buy” rating and set a £175 target price on shares of AstraZeneca in a research report on Wednesday. Jefferies Financial Group restated a “buy” rating and set a £175 target price on shares of AstraZeneca in a research report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £117 price target on shares of AstraZeneca in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price target on shares of AstraZeneca in a research report on Tuesday, September 8th.
Read Our Latest Stock Report on AstraZeneca
AstraZeneca Price Performance
Key Stories Impacting AstraZeneca
Here are the key news stories impacting AstraZeneca this week:
- Positive Sentiment: Analyst support remains strong: Jefferies reaffirmed its “buy” rating and set a £175 price target, while Berenberg also maintained a “buy” rating with a £175 target. Citi separately raised its target to 18,600 pence (£186), implying substantial upside from recent trading levels. Jefferies maintains buy rating Citi raises AstraZeneca target
- Positive Sentiment: Oncology pipeline strengthened: AstraZeneca’s investment in Summit Therapeutics is deepening its cancer pipeline and expanding its exposure to potentially important oncology programs. AstraZeneca Summit Therapeutics investment
- Positive Sentiment: Prostate-cancer collaboration: AstraZeneca is partnering with Myriad Genetics and SOPHiA GENETICS on prostate-cancer polygenic risk scores, a move that could support more personalized patient identification and treatment decisions. Prostate cancer risk-score partnership
- Neutral Sentiment: Market positioning: AstraZeneca was reported at about €142.63 with an approximately $248.3 billion market capitalization, underscoring its scale but offering limited new information for valuation. AstraZeneca market capitalization
- Negative Sentiment: Recent trading weakness: AstraZeneca fell and underperformed the broader market, while a separate report noted that the shares reached a new 12-month low. The decline suggests near-term selling pressure is outweighing favorable broker commentary and pipeline news. AstraZeneca underperforms market AstraZeneca reaches 12-month low
Insider Activity at AstraZeneca
In other AstraZeneca news, insider Michel Demare bought 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The stock was acquired at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by company insiders.
AstraZeneca Company Profile
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Featured Stories
- Five stocks we like better than AstraZeneca
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
